BP1, a homeoprotein, is significantly expressed in prostate adenocarcinoma and is concordant with prostatic intraepithelial neoplasia
BP1, a homeoprotein, is significantly expressed in prostate adenocarcinoma and is concordant with prostatic intraepithelial neoplasia
复制标题
DOI：
10.1038/modpathol.2008.168
复制
发表时间：
2009-01-01
期刊：
影响因子：
7.5
通讯作者：
Berg, Patricia E.
中科院分区：
文献类型：
--
作者：
Schwartz, Arnold M.;Man, Yan-Gao;Berg, Patricia E.
BP 1是对早期发育至关重要的转录因子同源盒基因超家族的成员。BP 1的显著mRNA表达和免疫组织化学反应性存在于大多数乳腺癌和所有炎性乳腺癌病例中。本研究试图确定BP 1表达是否在前列腺癌（另一种激素依赖性实体瘤）中可检测到，以及这种表达是否与组织病理学和预后因素相关。从前列腺癌组织登记处（NIH）获得的根治性前列腺癌切除术癌标本和前列腺癌组织微阵列切片的石蜡切片测定BP 1免疫反应性。由两名独立的病理学家使用三层系统（0，1+，2+）进行免疫反应性评分，并与Gleason评分和前列腺特异性抗原（PSA）生化复发相关。进行Ki-67（MIB-1）免疫反应性以评估增殖。Kappa和Cochran-Mantel-Haenszel统计分析用于评估观察者间一致性和病理生物学相关性。无论是在组织切片（50例）还是组织微阵列平台（123例）上进行分析，在大约70%的前列腺癌中鉴定出显著的BP 1免疫反应性（2+）。在< 5%的正常腺泡细胞中观察到BP 1免疫反应性。两个独立观察员之间的一致性非常好，kappa-statistics > 0.7。12例前列腺癌与前列腺上皮内瘤（PIN）配对病例的组织切片呈一致性强免疫反应。Gleason评分或前列腺特异性抗原（PSA）生化复发与BP 1免疫反应性强无关。Ki-67（MIB-1）免疫反应性测定的肿瘤增殖，在BP 1免疫反应性的癌细胞中高于BP 1非反应性的癌细胞。这些发现表明，BP 1是前列腺癌致癌途径中的重要上游因子，并且BP 1的表达可能反映或直接促成肿瘤进展和/或侵袭。
BP1 is a member of the homeobox gene superfamily of transcription factors that are essential for early development. Significant mRNA expression and immunohistochemical reactivity of BP1 is present in a majority of breast cancers and in all cases of inflammatory breast cancer. This study attempts to determine whether BP1 expression is detectable in prostate cancer, another hormone dependent solid tumor, and whether this expression correlates with histopathologic and prognostic factors. Paraffin sections from radical prostatectomy cancer specimens and from tissue microarray sections of prostate cancer, obtained from the Prostate Cancer Tissue Registry (NIH), were assayed for BP1 immunoreactivity. Immunoreactivity scoring by two independent pathologists, using a three-tiered system (0, 1+, 2+), was recorded and correlated with Gleason scoring and prostatic specific antigen (PSA) biochemical recurrence. Ki-67 (MIB-1) immunoreactivity was performed to assess proliferation. Kappa and Cochran-Mantel-Haenszel statistical analyses were used to assess interobserver agreement and pathobiologic correlations. Significant BP1 immunoreactivity (2+) was identified in approximately 70% of prostatic adenocarcinomas, whether the analysis was performed on tissue sections (50 cases) or tissue microarray platforms (123 cases). BP1 immunoreactivity was seen in < 5% of normal acinar cells. The agreement between two separate observers was very good, with kappa-statistics > 0.7. In tissue sections, 12 cases with paired carcinoma and prostatic intraepithelial neoplasia ( PIN) showed concordance with strong immunoreactivity. Gleason scores or prostatic specific antigen (PSA) biochemical recurrences were not correlated with strong BP1 immunoreactivity. Tumor proliferation, assayed with Ki-67 (MIB-1) immunoreactivity, was higher in cancer cells that were BP1 immunoreactive, relative to those that were BP1 non-reactive. These findings suggest that BP1 is an important upstream factor in the carcinogenic pathway of prostate cancer and that the expression of BP1 may reflect or directly contribute to tumor progression and/or invasion.